<a href="https://laohu8.com/S/KALA">Kala Bio</a> Faces Nasdaq Delisting Risk Over Market Value Compliance
Kala Bio Inc. has announced that it received a deficiency letter from the Nasdaq Stock Market, indicating that the company is not in compliance with Nasdaq Listing Rule 5550(b)(2). The rule requires a minimum market value of listed securities of $35 million, which Kala Bio failed to meet for 30 consecutive business days. The company also does not meet alternative continued listing standards, including minimum stockholders' equity or net income requirements. Kala Bio has been given 180 calendar days, until May 11, 2026, to regain compliance. If compliance is not achieved by the deadline, the company's securities may be subject to delisting, though Kala Bio would have the right to appeal the decision. The company intends to monitor its situation and consider available options to regain compliance with Nasdaq rules.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kala Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-110316), on November 12, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.